Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2019

Aug 14, 2019

SELL
$52.76 - $82.19 $1.85 Million - $2.89 Million
-35,159 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$27.39 - $68.41 $963,005 - $2.41 Million
35,159 New
35,159 $2.1 Million

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $270M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Graticule Asia Macro Advisors LLC Portfolio

Follow Graticule Asia Macro Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Graticule Asia Macro Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Graticule Asia Macro Advisors LLC with notifications on news.